Lukasz Szarpak,Michal Pruc,Magdalena Bizon et al.
Lukasz Szarpak et al.
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
周边T细胞和自然杀伤细胞淋巴瘤：ESMO-EHA临床实践指南（诊断、治疗及随访）
F d&#x;Amore,M Federico,L de Leval et al.
F d&#x;Amore et al.
LONG-TERM DEVELOPMENT OF 12- AND 15-YEAR-OLD OFFSPRING AFTER MATERNAL CANCER DIAGNOSIS DURING PREGNANCY: A PROSPECTIVE MULTICENTRE COHORT STUDY [0.03%]
母亲孕期诊断癌症后子女长期发育情况：一项前瞻性多中心队列研究
E A Huis In &#x;t Veld,I A Van Assche,K Van Calsteren et al.
E A Huis In &#x;t Veld et al.
Background: Evidence is lacking on the long-term effects of prenatal exposure to maternal cancer and its treatment on adolescent neurocognitive, cardiac, and physical health. ...
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives [0.03%]
人工智能在肿瘤学病理领域的应用及未来展望
A Marra,S Morganti,F Pareja et al.
A Marra et al.
Background: Artificial intelligence (AI) is rapidly transforming the fields of pathology and oncology, offering novel opportunities for advancing diagnosis, prognosis, and treatment of cancer. ...
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study [0.03%]
一种新型nectin-4靶向抗体偶联药物（9MW2821）在晚期实体瘤患者中的i/ii期首次人体开放多中心临床研究
J Zhang,R Liu,S Wang et al.
J Zhang et al.
Backgroud: A first-in-human study was performed to assess the safety and preliminary antitumor activity of 9MW2821, a next-generation monoclonal antibody-drug conjugate (ADC) that delivers monomethylauristatin E (MMAE) to...
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population [0.03%]
人群BRCA1/2基因突变类型及位点与乳腺癌风险的关联性研究
M P Akamandisa,N J Boddicker,S Yadav et al.
M P Akamandisa et al.
Background: Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. However, it is unknown whether this risk differs by PV type or location in carriers ascertaine...
Editorial to introduce article "Enrichment of CD7+CXCR3+ CAR T cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma" [0.03%]
“CD7+CXCR3+CAR-T细胞回输产品中强化富集与复发/难治弥漫大B细胞淋巴瘤患者持久缓解相关”——编者按（附CXCR3定向CAR-T细胞治疗r/r DLBCL患者的临床试验文章）
J-M Michot,C Bigenwald
J-M Michot
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa [0.03%]
开放式与机器人辅助部分肾切除术治疗中高复杂度肾脏肿瘤患者的疗效：OpeRa随机对照多中心试验的最终结果
M-O Grimm,J Bedke,J Nyarangi-Dix et al.
M-O Grimm et al.
Background: The prospective, randomised, open-label, multicentre OpeRa trial (NCT03849820) aimed to determine whether robotic-assisted partial nephrectomy (RAPN) is superior to open partial nephrectomy (OPN) in reducing 3...
Copenhagen Prospective Personalized Oncology (CoPPO) - Impact of comprehensive genomic profiling in more than 2000 patients in a Phase I setting [0.03%]
哥本哈根精准肿瘤学展望（CoPPO）——在一期临床试验中，全面基因组检测对超过两千患者的影响
L Belcaid,M Højgaard,I Tuxen et al.
L Belcaid et al.
Purpose: Targeted therapy based on the molecular characterization of tumors has been among the most remarkable advances in cancer medicine. Here, we report the impact of almost 10 years of comprehensive genomic profiling ...
Corrigendum to "Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma": [Annals of Oncology 30 (2019):990-997] [0.03%]
多灶性肝细胞癌的基因组和转录异质性的勘误说明：《肿瘤学年鉴》(2019)30:990-997
L X Xu,M H He,Z H Dai et al.
L X Xu et al.